FULC · Fulcrum Therapeutics, Inc.
$3.75
+0.08 (+2.18%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$286.50M
Shares
76.30M
Volume · Oct 8
2.63M
Avg daily vol (3M)
1.55M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.75
Open$3.66
Day$3.66–3.78
52W close$3.14–14.60
Avg vol 30d1.4M
Short int7.2M · 9.4% float · 5.9d
Short vol36%
Last earningsApr 27, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 30
Up next
filed Jul 30, 2026
call held Apr 27, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$85.00M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.9%
Year over year · more shares
Price change (1Y)
-60.3%
Trailing year
Short interest
9.4%
Latest settlement · 5.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
5%
near low
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−55%
trailing
YTD return
−67%
this year
Relative strength
−64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
3 of 154 funds reported for Sep 30 · net +899 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.43% of float · ▲ +2.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
154 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−638%
Y/Y
Free cash flow
$-60.4M
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2022
into mid-2024
Savings in operating expenses
$40M – $50M
Cash charges related to the realignment plan consisting of one-t
$400,000 – $500,000
Workforce reduction of planned headcount
25%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
3 of 154 funds reported for Sep 30 · net +899 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.43% of float · ▲ +2.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
154 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 5%
Range high $15
vs 200-day avg -42%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FULC
this stock
Fulcrum Therapeutics, Inc.
|
$286.50M | -66.8% | -100.0% | — | 9.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.0% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FULC | +1.9% | -1.3% | -54.8% | +1.4% | -66.8% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | +0.6% | -3.4% | -63.7% | -0.1% | -80.3% |